Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Paraproteinemias 1Neoplasms 1

Interventions

Rituximab 16ibrutinib 9Bortezomib 8fludarabine phosphate 7Lenalidomide 6Cyclophosphamide 5Bendamustine Hydrochloride 5Peripheral Blood Stem Cell Transplantation 4Flow Cytometry 4Dasatinib 4tanespimycin 3pomalidomide 3belinostat 3Vorinostat 3Polymerase Chain Reaction 3Pharmacogenomic Testing 3Melphalan 3Everolimus 3Etoposide 3Dexamethasone 3ublituximab 2nelarabine 2ibritumomab tiuxetan 2fludarabine 2carfilzomib 2alvocidib 2Tacrolimus 2Methotrexate 2Magnetic Resonance Spectroscopy 2MLN 8237 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Waldenstrom Macroglobulinemia × Rifaximin × Clear all
NCT03820817 2026-05-26

Rifaximin in Patients With Monoclonal Gammopathy

Emory University

Phase 1 Completed
50 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡